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Abstract
Glucagon-like peptide 2 (GLP2) is a proglucagon-derived peptide produced by intestinal 
enteroendocrine L-cells and by a discrete population of neurons in the brainstem, which 
projects mainly to the hypothalamus. The main biological actions of GLP2 are related 
to the regulation of energy absorption and maintenance of mucosal morphology, 
function and integrity of the intestine; however, recent experimental data suggest 
that GLP2 exerts beneficial effects on glucose metabolism, especially in conditions 
related to increased uptake of energy, such as obesity, at least in the animal model. 
Indeed, mice lacking GLP2 receptor selectively in hypothalamic neurons that express 
proopiomelanocortin show impaired postprandial glucose tolerance and hepatic insulin 
resistance (by increased gluconeogenesis). Moreover, GLP2 acts as a beneficial factor 
for glucose metabolism in mice with high-fat diet-induced obesity. Thus, the aim of this 
review is to update and summarize current knowledge about the role of GLP2 in the 
control of glucose homeostasis and to discuss how this molecule could exert protective 
effects against the onset of related obesity type 2 diabetes.
Introduction
Glucagon-like peptide 2 (GLP2) is a 33 amino acid 
proglucagon-derived peptide produced by a subset 
of enteroendocrine cells (L-cells) residing within the 
epithelium of the small and large intestine (Yusta et  al. 
2000). GLP2 is also produced in a discrete population of 
neurons in the brainstem, which projects mainly to the 
hypothalamus, brain area that plays a key role in control 
of food intake (Vrang et al. 2007). Prohormone convertase 
1/3 (PC1/3) processes proglucagon in the gastrointestinal 
tract and in the brain, resulting in glucagon-like peptide-1 
(GLP1), GLP2, intervening peptide-2, oxynthomodulin 
and glicentin (Ugleholdt et  al. 2004). The studies on 
proglucagon-derived peptides have supplied two classes 
of glucose-lowering agents, the dipeptidyl peptidase 
IV (DPP-IV) inhibitors and GLP1 receptor agonists, 
useful tools for the treatment of type 2 diabetes (T2D) 
(Drucker & Nauck 2006). However, the overwhelming 
interest attracted by GLP1 analogues as potent incretins 
has somewhat clouded the efforts to understand the 
importance of other proglucagon-derived peptides. 
In fact, unlike GLP1, initially, GLP2 was not reported 
to modulate insulin secretion or glucose homeostasis 
(Schmidt et al. 1985, Ørskov et al. 1988); however, recent 
experimental data suggest that GLP2 exerts beneficial 
effects on glucose metabolism, especially in conditions 
related to increased uptake of energy, such as obesity, at 
least in the animal model (Cani et al. 2009, Bahrami et al. 
2010, Shi et al. 2013, Guan 2014, Baldassano et al. 2015). 
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Thus, the aim of this review is to update and summarize 
current knowledge about the role of GLP2 in the control 
of glucose homeostasis and to discuss how this molecule 
could exert protective effects against the onset of related 
obesity type 2 diabetes.
Overview on GLP2
GLP2 was first discovered as an intestinotrophic factor in 
1996 (Drucker et al. 1996); however, today it is considered 
a pleiotropic hormone with a wide range of effects, mainly 
in the gastrointestinal tract. The main biological actions 
of GLP2 are related to the regulation of energy absorption 
and maintenance of mucosal morphology, function and 
integrity of the intestine (Drucker & Yusta 2014 for an 
extensive review).
GLP2 is released in response to stimulation by 
luminal nutrients, such as glucose, fatty acids and 
dietary fibre (Brubaker 2006). GLP2 is cleaved to 
inactive GLP2 (3–33) by DPP-IV; consequently, the half-
life of intravenous GLP2 is very short, about 7 min in 
healthy humans (Hartmann et  al. 2000). Indeed, GLP2 
(3–33) may act as a weak agonist at pharmacological 
concentrations (Shin et  al. 2005); however, it is able to 
act as a competitive antagonist of the GLP2 receptor 
(GLP2R) in rodents (Thulesen et al. 2002, Shin et al. 2005, 
Baldassano et al. 2009, 2013). Then DPP-IV-resistant GLP2 
analogues, such as [Gly2]-GLP2 (teduglutide), exhibit 
greater bioactivity relative to native molecule, due to 
their longer circulating half-lives (Tavares et  al. 2000, 
Baldassano & Amato 2014).
GLP2 promotes energy absorption within the 
gastrointestinal tract through non-specific and specific 
adaptation. In fact, it induces crypt cell proliferation and 
inhibition of apoptosis, resulting in an increase of villous 
height and in the expansion of the absorptive mucosal 
surface in the small and large intestine (Drucker et al. 1996, 
Tsai et al. 1997, Drucker & Yusta 2014). Moreover, GLP2 
increases the uptake of sugars by augmenting the activity 
and the expression of transporters (Cheeseman 1997, Au 
et al. 2002, Ramsanahie et al. 2004, Sueyoshi et al. 2014) 
and by enhancing the expression of different enzymes 
involved in digestion (Brubaker et  al. 1997a, Petersen 
et al. 2002). Evidence from studies on humans and animal 
models suggests that GLP2 also plays a role in lipid 
absorption. Indeed, GLP2 facilitates intestinal absorption 
of lipids (Meier et al. 2006, Hsieh et al. 2009) and enhances 
and regulates chylomicron secretion from the intestine 
(Hsieh et al. 2009, Hein et al. 2013, Dash et al. 2014).
The gastrointestinal responses to GLP2 are mediated 
via GLP2R, a member of the glucagon/secretin G protein-
coupled receptor superfamily that is located on enteric 
(Bjerknes & Cheng 2001, Baldassano et al. 2009) and vagal 
nerves (Nelson et  al. 2007), subepithelial myofibroblasts 
(Ørskov et  al. 2005) and a subset of intestinal epithelial 
cells (Thulesen et al. 2000). Activation of GLP2 receptors 
regulates epithelial cell growth (Tsai et al. 1997, Bjerknes & 
Cheng 2001), reduces intestinal permeability, enhances 
the barrier function (Benjamin et  al. 2000, Moran et  al. 
2012, Drucker & Yusta 2014), increases mesenteric blood 
flow (Guan et  al. 2006, Stephens et  al. 2006, Bremholm 
et  al. 2009) and inhibits gastrointestinal motility, thus 
providing another mechanism to increase digestion and 
absorption of nutrient (Wøjdemann et al. 1998, McDonagh 
et al. 2007, Amato et al. 2009, 2010, Cinci et al. 2011).
GLP2R is also expressed in the central nervous system 
(CNS), specifically in key regions of the brain for energy 
balance, including the hypothalamus, hippocampus and 
brainstem (Tang-Christensen et  al. 2000, Lovshin et  al. 
2004, Guan et  al. 2012). As a neurotransmitter, GLP2 
may mediate preproglucagonergic (PPG) neuron-induced 
synaptic transmission linking the hypothalamus and 
the brainstem and may act as a satiation signal in the 
control of feeding behaviour (Tang-Christensen et  al. 
2000). In fact, intracerebroventricular administrations of 
GLP2 reduce food intake in rodents (Tang-Christensen 
et  al. 2000, Lovshin et  al. 2001). In addition, knockout 
mice with GLP2R deletion selectively in hypothalamic 
arcuate nucleus neurons expressing proopiomelanocortin 
(POMC) display hyperphagic behaviour and late-onset 
obesity (Guan et  al. 2012). These observations support 
the hypothesis of a physiological role in the regulation of 
food intake and body weight (Guan et  al. 2012). Up to 
date, studies in humans have not demonstrated a decrease 
in food intake after peripheral GLP2 administration 
(Schmidt et al. 2000, Sørensen et al. 2003), even if recent 
data have shown that intraperitoneal injections of GLP2 
or [Gly2]-GLP2 reduce food intake in mice, suggesting a 
role for GLP2 in the short-term regulation of the eating 
behaviour (Baldassano et  al. 2012). This effect is related 
to a significant decrease in the rate of gastric emptying 
(Baldassano et al. 2012), and it is well known that gastric 
emptying is a critical process for the short-term control 
of food intake (Janssen et al. 2011, Rotondo et al. 2011a). 
Moreover, in mice, GLP2R deletion in POMC neurons 
accelerates the rate of gastric emptying accounting for the 
hyperphagic behaviour and supporting the hypothesis 
that CNS GLP2 is a key satiety signal for the physiological 
short-term control of feeding behaviour (Guan et al. 2012).
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GLP2 and glycaemic control
Up to date, the GLP2 action on glucose homeostasis has 
been scarcely investigated, and the importance of GLP2R 
signalling is not clear yet (Guan 2014). GLP2R global 
deficiency is not critical for glucose homeostasis in normal 
or lean diabetic mice because it is not associated with 
changes in fasting glucose, glucose tolerance or plasma 
glucagon level (Bahrami et al. 2010). Also the observation 
that the chronic treatment with GLP2 (3–33), a GLP2R 
antagonist used to reveal the physiological actions of 
GLP2 (Shin et al. 2005, Nelson et al. 2008, Iakoubov et al. 
2009, Baldassano et al. 2013), does not affect glycaemic 
parameters, glucose tolerance, insulin sensitivity or 
pan creas weight and β-cell mass in mice, has led to rule out 
a role for the endogenous GLP2 in glucose homeostasis in 
normal conditions (Baldassano et al. 2015). In addition, 
changes in glucagon levels or glycaemia have not been 
reported following acute or chronic GLP2 or teduglutide 
administration in patients with short bowel syndrome 
(Drucker & Yusta 2014).
We know for a long time that GLP2 does not exhibit 
any insulin-releasing properties (Schmidt et  al. 1985, 
Ørskov et al. 1988). On the contrary, i.v. infusion of the 
peptide has been demonstrated to increase glucagon 
secretion in healthy, non-obese human subjects both in 
physiological and pharmacological plasma concentration 
(Sørensen et  al. 2003, Meier et  al. 2006) or in diabetic 
patients (Christensen et  al. 2010, Lund et  al. 2011). 
GLP2R has been localized to α-cells in both human and 
rat islets by means of immunohistochemistry as well as 
real-time PCR (de Heer et al. 2007). In contrast, full-length 
Glp2r mRNA transcripts have not been detected in RNA 
from murine islets, and GLP2 does not increase plasma 
glucagon levels in mice (Yusta et al. 2000, Bahrami et al. 
2010). The discrepancy could be attributed to different 
species; however, caution should be taken in ruling out 
a glucagonotrophic role of GLP2 in mice. In fact, recent 
researches have demonstrated that GLP2R is more widely 
expressed than it was estimated (Angelone et  al. 2012, 
El-Jamal et al. 2014). Therefore, it is necessary to explore 
the presence and localization of GLP2R in the pancreatic 
islets using validated GLP2R antibody and the opportune 
positive and negative controls to yield to conclusive 
results. Anyway, the GLP2 glucagonotrophic properties 
could suggest that the endogenous or exogenous peptide 
exacerbates the hyperglycaemia conditions related to 
diabetes. Nevertheless, the glucagon hypersecretion 
induced by oral glucose, which is typical of patients 
with T2D (Knop et  al. 2007), is not a consequence of 
exaggerated secretion or effect of GLP2 (Lund et  al. 
2011), and GLP2R global absence in genetically obese 
mice increases glucagon secretion and hyperglycaemia 
(Bahrami et al. 2010). Therefore, the importance of GLP2 
in the control of glucagon secretion in different species 
and in diverse pathological conditions related to glucose 
impairment requires further elucidation.
New evidence obtained from GLP2R tissue-specific 
KO mice indicates that GLP2R in POMC neurons is 
essential for suppressing hepatic glucose production (Shi 
et  al. 2013). Indeed, mice lacking GLP2R selectively in 
POMC neurons display impaired postprandial glucose 
tolerance and hepatic insulin resistance (by increased 
gluconeogenesis), suggesting a physiological significance 
of GLP2 neural action in glycaemic control. Moreover, 
intracerebroventricular infusion of GLP2 increases glucose 
tolerance and insulin sensitivity and suppresses basal 
hepatic glucose production through GLP2R activation in 
POMC neurons (Shi et al. 2013). Therefore, GLP2 has been 
proposed as a crucial neuroendocrine signal for glucose 
homeostasis (Guan 2014). It will be crucial to determine 
whether CNS GLP2R is a key contributor to glycaemic 
control and insulin sensitivity also in humans.
Moreover, GLP2 seems to act as a beneficial factor 
for glucose metabolism in obesity condition. Loss of 
GLP2R leads to increased glucagon secretion and α-cell 
mass, impaired intraperitoneal glucose tolerance and 
hyperglycaemia, reduced β-cell mass and decreased islet 
proliferation in genetic obese ob/ob:Glp2r-/- mice. Then, 
the authors have suggested that GLP2R is required for the 
adaptation of the endocrine pancreas to metabolic stress 
(Bahrami et al. 2010). In mice fed a high-fat diet (HFD), 
endogenous GLP2 acts as a protective factor against 
the dysregulation of glucose metabolism that occurs in 
HFD-fed mice because GLP2 (3–33) chronic treatment 
exacerbates glucose metabolism disorders (Baldassano 
et  al. 2015). It is well known that in C57BL/6J mouse 
model, a chronic exposure to HFD induces obesity 
and a progressive deterioration of metabolic control, 
characterized by hyperglycaemia, hyperinsulinaemia and 
peripheral and central insulin resistance (Surwit et  al. 
1988, Ahrén et  al. 1997, Lee et  al. 1995, Nuzzo et  al. 
2015). Mice after 10 weeks on HFD have greater mass 
gain compared with standard diet-fed mice, show 
hyperglycaemia, an impaired glycaemic response 
following intraperitoneal glucose load, high plasma 
insulin level after glucose load, increased pancreas 
weight and β cell expansion, but not insulin resistance. In 
HFD-fed mice, GLP2 (3–33) treatment for 4 weeks (from 
the sixth to the tenth week of diet) does not affect fasting 
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glycaemia; however, it significantly increases glucose 
intolerance, enhances both fasting and glucose-induced 
insulin concentrations and reduces sensitivity to insulin. 
Therefore, the reduc tion of GLP2R signalling accelerates 
the process leading to insulin resistance in HFD-fed mice 
(Baldassano et  al. 2015). On the contrary, long-term 
exposure to GLP2 stable analogue improves the obesity-
related glucose dysmetabolism in a concentration-
dependent manner (Baldassano et  al. 2016a). In fact, 
HFD-fed mice treated with pharmacological doses of 
Gly2-GLP2 for 4 weeks show a significant increase in 
glucose tolerance and exogenous insulin sensitivity and 
reduction in glucose-stimulated plasma insulin levels 
in comparison with pair-aged HFD-untreated animals, 
suggesting that the peptide is able to delay the onset 
of insulin resistance (Baldassano et  al. 2016a). Indeed, 
a previous study has described the failure of GLP2 to 
modify diabetes onset in non-obese diabetic mouse, a 
model of type 1 diabetes (T1D) (Hadjiyanni et al. 2009). 
Therefore, due to different aetiology of T1D compared 
with T2D, it could be proposed that the protective 
role is associated exclusively with obesity conditions. 
An association between insulin resistance and GLP2 
secretion has been found in a pilot study on obese 
human subjects (Geloneze et  al. 2013). Hypothesis has 
been advanced that GLP2-increased secretion could 
be the cause of insulin resistance as GLP2 increases 
absorption of nutrients, especially fatty acids, a key factor 
for insulin resistance (Delarue & Magnan 2007) or for its 
glucagonotrophic action in healthy or diabetic subjects 
(Christensen et al. 2010, Lund et al. 2011). Glucagon is 
counter-regulatory to insulin action, increasing glucose 
output and inhibiting glucose uptake in the liver, and 
it has been linked to insulin resistance in obese subjects 
with normal or impaired glucose tolerance (Ahrén 
2006, Weiss et al. 2011). However, this appears unlikely 
because bariatric surgery, particularly Roux-en-Y gastric 
bypass (RYGB) (Saeidi et  al. 2013), which is the most 
effective therapy for obesity and T2D (Carlsson et  al. 
2012, Cummings 2012), increases blood GLP2 (by 200%) 
at postprandial status (le Roux et  al. 2010). Bariatric 
surgery normalizes blood glucose concentrations in 
the majority of T2D humans independent of weight 
loss (Mingrone et al. 2012, Schauer et al. 2012) and can 
induce diabetes remission up to 6 years (Cohen et  al. 
2012). It is likely that the enhancement of nutrient 
flux into the distal small intestine after bariatric surgery 
triggers a signal leading to an antidiabetic effect that 
does not appear related to gastric inhibitory peptide 
(GIP) or GLP1 (Breen et  al. 2013). In fact, changes in 
circulating GLP1 are not consistent between models of 
diabetes that received duodenal–jejunal bypass (Breen 
et  al. 2012). Moreover, bariatric surgery still improves 
glucose tolerance in GLP1 receptor-deficient HFD-fed 
mice (Wilson-Pérez et  al. 2013). Therefore, GLP2 could 
be responsible for glycaemic improvement after bariatric 
surgery and can be considered as a key signal to drive 
intestinal reprogramming of glucose metabolism (Saeidi 
et al. 2013). In addition, animal studies have shown that 
GLP2 secretion from ileal tissue is decreased in diabetic 
conditions (Shan et  al. 2013), and reduced numbers of 
L-cells have been detected in the intestinal tissue from 
HFD-fed mice compared with intestinal tissue from mice 
receiving a control diet (Kappe et  al. 2014). Therefore, 
GLP2-decreased production might lead to T2D. Further 
studies are needed to clarify definitively whether and 
how GLP2 is involved in the improvement of glycaemic 
control after bariatric surgery.
We speculate that GLP2 may act as a protective factor 
against the deregulation of the glucose metabolism that 
occurs in obese conditions. Of note, in obese patients 
without T2D, GLP2 concentrations in plasma are higher 
(8500 pg/mL) (Valderas et  al. 2014) than in healthy 
human subjects (851 ± 230 pg/mL) (Brubaker et al. 1997b). 
These GLP2 plasma high levels can be interpreted as a 
beneficial factor against T2D development. Also HFD-fed 
obese mice show GLP2 plasma levels higher than those 
in lean animals (Baldassano et  al. 2013) and increased 
gut gene and protein expression of GLP2R (Rotondo 
et al. 2011b, Baldassano et al. 2013). Although nothing 
is known about the expression in human individuals, 
the positive correlation between GLP2 plasma levels 
and GLP2R mRNA and protein abundance indicates that 
Glp2r expression is not negatively affected by increased 
plasma GLP2 concentrations and could be interpreted 
as an adaptive signal involved in the regulation of 
glucose metabolism in conditions of obesity. In fact, 
as endogenous GLP2 causes a trophic effect on the 
mucosa of the small intestine with increased absorptive 
surface in HFD-fed obese mice (Baldassano et al. 2013), 
the hormone could aim to preserve and improve the 
glucose metabolic disorders induced by HFD. Although 
down-regulation after exposure to the receptor ligand 
is a common phenomenon, diverse studies report 
that  exogenous GLP2 or inhibition of DDPIV (which 
doubles GLP2 levels) augments GLP2R expression in 
ileum and jejunum (Koopmann et  al. 2008, Sueyoshi 
et al. 2014).
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Mechanistic insight
The mechanisms underlying the beneficial effect of GLP2 
on glucose metabolism remain to be established.
About glucose homeostasis in healthy mice, an 
elegant, recent work has pointed out that GLP2 can 
surely act in the CNS. In fact, GLP2 is able to modulate 
the excitability of POMC neurons in GLP2R- and PI3K-
dependent manner (Shi et  al. 2013). Hypothesis has 
been advanced that GLP2 activates POMC neurons 
to release α-melanocyte-stimulating hormone. This 
hormone activates melano cortin receptor 4-positive 
cholinergic neurons of vagal dorsal motor nucleus that 
enhance hepatic vagal output to suppress hepatic glucose 
production (Guan 2014). Alternatively, GLP2 may activate 
neurons in the nucleus of the solitary tract via afferent 
vagal inputs to modulate glucose metabolism. In fact, 
GLP2 activates vagal afferent pathways where GLP2R is 
expressed (Nelson et al. 2007). Although GLP2-modulated 
neural circuitries have not been fully defined, it has been 
speculated that GLP2R activation on vagal afferents 
may influence the preproglucagonergic neurons in the 
brainstem nucleus of solitary tract with consequent release 
of GLP2-activating hypothalamic neurons and vagal 
outputs from dorsal motor nucleus to regulate control of 
feeding behaviour and glucose homeostasis (Guan 2014). 
Anyway, according to these hypotheses, the glycaemic 
control by GLP2 involves fine-tuning vagal outputs. One 
problem is represented by the identification of the GLP2 
source (endocrine L-cells or PPG neurons), responsible for 
the control of glucose metabolism. Of note, to date, to 
our knowledge, there is no report on the passage of GLP2 
across the blood–brain barrier (BBB); however, peripheral 
hormone could act in the hypothalamic arcuate nucleus 
where BBB is semipermeable.
The molecular mechanisms and the tissue targets 
underlying the beneficial effect of GLP2 on glucose 
metabolism in obese/HFD-fed mice have not been 
established yet (Baldassano et  al. 2015, 2016a), but 
different speculations may be made (Fig. 1).
Because no changes in body weight or in the daily 
food intake have been observed in GLP2 (3–33)- or 
Gly2-GLP2-treated mice in comparison with untreated 
animals, an indirect effect mediated by an anti-obesity 
action has been ruled out (Baldassano et al. 2015, 2016a). 
It is well known that reduced adiposity could contribute 
to the preservation of insulin sensitivity because the 
adipose tissue has a considerable influence on systemic 
glucose homeostasis through secretion of adipocytokines 
(McArdle et al. 2013). Interestingly, Glp2r mRNA expression 
has been detected in mouse mesenteric adipose tissue 
(El-Jamal et al. 2014); however, its functional significance 
is still unknown. It is important to characterize whether 
GLP2 increases glucose incorporation in adipocytes 
when their response to insulin is impaired by obesity 
conditions. In fact, although there are conflicting reports 
regarding the alterations in the basal glucose uptake, most 
reports provide evidence that insulin-induced glucose 
incorporation is suppressed in the obese state (Talior et al. 
2003, Sancho et al. 2006, Crowe et al. 2008), and as GLP2 
Figure 1
Hypothetical targets and relative actions 
responsible for the beneficial effects of GLP2 on 
glucose dysmetabolism in HFD-fed obese mice.  
A full colour version of this figure is available at 
http://dx.doi.org/10.1530/JOE-16-0035.
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rapidly increases intestinal hexose absorption (Cheeseman 
1997, Au et al. 2002), it is not unlikely to hypothesize that 
it contributes to clearance of plasma glucose through an 
action on adipocytes. In addition or alternatively, GLP2 
might influence and modulate the quality and quantity 
of secreted adipokines and the inflammatory state of 
adipose tissue.
Another hypothetical target for GLP2 could be 
represented by pancreas. Indeed, a direct action on 
β-cell function is improbable because the Glp2r mRNA 
transcripts have not been detected in pancreatic islets, 
but only in mouse whole pancreas (Bahrami et al. 2010) 
or rat and human pancreatic α-cells (de Heer et al. 2007). 
Despite exogenous GLP2 increases glucagon secretion 
(Meier et  al. 2006, de Heer et  al. 2007), elimination of 
GLP2R signalling in genetically obese mice leads to 
increased glucagon secretion and α-cell mass, which has 
been interpreted as due to increased proinflammatory 
signals (Bahrami et al. 2010), for example interleukin-6, 
in turn, involved in α-cell mass expansion (Ellingsgaard 
et al. 2008). Unluckily, glucagon levels were not measured 
in HFD-fed mice after GLP2 (3–33) or Gly2-GLP2 chronic 
treatment. Of note, GLP2 and GLP2R expression might 
change following HFD, as reported in gut tissue (Rotondo 
et  al. 2011b, Baldassano et  al. 2013). Moreover, recent 
studies on glucose-dependent insulinotrophic polypeptide 
(GIP) and GLP1 have pointed out that both hormones 
are synthesized and secreted from islet α-cells under 
conditions of cellular stress imposed by β cytotoxic attack 
or increased insulin demand (Fujita et al. 2010, Donath & 
Burcekin 2013, Moffett et al. 2014). Increased expression 
of PC1/3 relative to PC2 in islet α-cells directs proglucagon 
processing away from glucagon towards GLP1 in these 
conditions (Wideman et al. 2007, Marchetti et al. 2012). 
As GLP1 and GLP2 are produced by the same convertase 
in equimolar amount (Janssen et al. 2013), it is likely to 
hypothesize that GLP2 pancreatic expression also changes 
in stress conditions, such as derangements of islet cell 
function associated with prolonged consumption of HFD. 
Therefore, before reaching any conclusions about a link 
between GLP2 and pancreas function, it is necessary to 
verify whether GLP2 and GLP2R expressions in pancreatic 
islets also change consistently with their beneficial role in 
glucose metabolism.
It is also possible that GLP2 acts directly on the 
liver to modulate hepatic function related to glucose 
or lipid metabolism. Mouse liver expresses GLP2R 
(El-Jamal et al. 2014); however, nothing is known about 
other species, including humans. Moreover, fatty liver 
is strongly associated with insulin resistance (Asrih & 
Jornayvaz 2013), and non-alcoholic hepatic steatosis has 
been reported in HFD-fed mice (de Meijer et  al. 2010, 
Fraulob et  al. 2010). Indeed, in HFD-fed mice, chronic 
treatment with GLP2 (3–33) aggravates dyslipidaemia 
and hepatic lipid accumulation. It increases plasma 
triglyceride, cholesterol, ALT and AST levels, intrahepatic 
lipid concentration, reduces HDL and exacerbates the 
liver steatosis, suggesting that endogenous GLP2 may 
exert defensive role against lipid imbalance in obesity 
condition (Baldassano et  al. 2016b). However, chronic 
administration of Gly2-GLP2 for 4 weeks is not associated 
with remarkable improvements in dyslipidaemia-related 
circulating parameters, and it does not prevent liver 
fat accumulation and the presence of microvesicular 
steatosis, suggesting that the level of insulin sensitivity 
in peptide-treated mice is not related to an apparently 
less severe tissue fat infiltration. Therefore, the beneficial 
effects of GLP2 chronic treatment on insulin sensitivity 
do not seem to be a consequence of an improvement in 
lipid metabolism (Baldassano et al. 2016a).
Another potential account for explaining endogenous 
or exogenous GLP2-protective effects against insulin 
resistance is related to GLP2 ability to reduce gut 
permeability and consequently the leakage of bacterial 
endotoxins into the portal blood circulation (Benjamin 
et  al. 2000). Endotoxemia and low-grade inflammation 
have been associated with insulin resistance (Hotamisligil 
2006, Cani et  al. 2007), and activation of inflammatory 
pathways has emerged as an imperative link between 
T2D and obesity (Hameed et al. 2015). It is well accepted 
that GLP2 is involved in modulation of intestinal 
permeability (Moran et al. 2012). In diabetic rats, plasma 
lipopolysaccharide, zonulin 1 expression, insulin level and 
insulin-resistant index are closely related to GLP2 levels 
(Shan et al. 2013). On the basis of these observations, the 
authors advanced the very suggestive hypothesis that 
impaired GLP2 in prediabetic subjects may predispose 
these patients to T2D by increasing intestinal permeability 
and endotoxemia-related inflammation. However, 
prospective studies in humans are needed. They found that 
glutamine-induced GLP2 secretion is decreased in rats with 
streptozotocin-induced experimental diabetes (Shan et al. 
2013). Impaired GLP1 secretion is a characteristic of the 
prediabetic situation such as impaired glucose tolerance 
and gestational diabetic mellitus (Lim & Brubaker 2006) 
and likely also GLP2 secretion from  the same L-cells is 
impaired. However, the fasting plasma GLP2 concentrations 
reported in humans with glucose dysmetabolism (Gjesing 
et al. 2011) or patients with T2D (Aaboe et al. 2010) are 
lesser than those in healthy human subjects (Brubaker 
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et al. 1997b). Also obese mice exhibit an altered gut barrier 
(Brun et al. 2007), and increased endogenous production 
of GLP2 induced by prebiotic diet improves gut barrier 
function (Cani et al. 2009). In fact, the block of the GLP2R 
exacerbates inflammation, whereas therapy with GLP2 
reduces systemic and hepatic inflammation in ob/ob mice 
(Cani et al. 2009). Therefore, it is conceivable that GLP2 
by enhancing epithelial barrier function and limiting the 
activation of processes that drive inflammation (Moore 
et  al. 2010) can delay and reduce the development of 
insulin resistance. However, this hypothesis needs to 
be verified.
Conclusion and perspective
New evidence underlines the importance of GLP2 in 
promoting the control and insulin sensitivity in animal 
model, particularly in conditions associated with obesity. 
Results from human studies so far remain inconsistent; 
therefore, future research should be addressed to 
clarify the role of GLP2 in preventing human insulin 
resistance and, in turn, the development of T2D. The 
potential mechanisms driving the beneficial effects of 
GLP2 receptor activation may be multiple and not fully 
elucidated. Greater attention should also be given to 
investigate on this hormone and its receptor as targets for 
treatment of obesity-associated diabetes in consideration 
of the chemical strategies for the design of multifunc-
tional peptides.
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